Chapter 7. Engineering Herpes Simplex Virus for Cancer Oncolytic Virotherapy

  1. Arsénio M. Fialho3 and
  2. Ananda M. Chakrabarty4
  1. Jason S. Buhrman1,2,
  2. Tooba A. Cheema1 and
  3. Giulia Fulci1

Published Online: 18 AUG 2010

DOI: 10.1002/9780470626528.ch7

Emerging Cancer Therapy

Emerging Cancer Therapy

How to Cite

Buhrman, J. S., Cheema, T. A. and Fulci, G. (2010) Engineering Herpes Simplex Virus for Cancer Oncolytic Virotherapy, in Emerging Cancer Therapy (eds A. M. Fialho and A. M. Chakrabarty), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470626528.ch7

Editor Information

  1. 3

    Institute for Biotechnology and Bioengineering (IBB), Center for Biological and Chemical Engineering, Instituto Superior Tecnico, Lisbon, Portugal

  2. 4

    Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL, USA

Author Information

  1. 1

    Massachusetts General Hospital, Harvard Medical School, MA, USA

  2. 2

    University of Illinois at Chicago School of Medicine, IL, USA

Publication History

  1. Published Online: 18 AUG 2010
  2. Published Print: 16 JUL 2010

ISBN Information

Print ISBN: 9780470444672

Online ISBN: 9780470626528

SEARCH

Keywords:

  • engineering herpes simplex virus - for cancer oncolytic virotherapy;
  • targeting HSV to cancer cells;
  • current limitations of oncolytic virotherapy

Summary

This chapter contains sections titled:

  • Introduction

  • Oncolytic Viruses

  • Targeting HSV to Cancer Cells

  • Combination Therapy Involving the Oncolytic HSV Virus

  • Clinical Trials with Oncolytic HSV

  • Current Limitations of Oncolytic Virotherapy

  • Conclusions and Future Perspectives

  • Acknowledgments

  • References